The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Richard Stone | EBMT 2019 | Role of FLT3 inhibitors in the treatment landscape of AML

Mar 25, 2019

45th Annual Meeting of the EBMT, 24—27 March 2019, Frankfurt, DE
Richard Stone
Dana-Farber Cancer Institute, Boston, US

Role of FLT3 inhibitors in the treatment landscape of AML